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Summary
Background Many cancer types display sex and age disparity in incidence and out-
come. The mutational load of tumours, including melanoma, varies according to
sex and age. However, there are no tools to explore systematically whether clini-
cal variables such as age and sex determine the genomic landscape of cancer.
Objectives To establish a mathematical approach using melanoma mutational data
to analyse how sex and age shape the tumour genome.
Methods We model how age-related (clock-like) somatic mutations that arise dur-
ing cell division, and extrinsic (environmental ultraviolet radiation) mutations
accumulate in cancer genomes.
Results Melanoma is driven primarily by cell-intrinsic age-related mutations and
extrinsic ultraviolet radiation-induced mutations, and we show that these muta-
tion types differ in magnitude and chronology and by sex in the distinct molecu-
lar melanoma subtypes. Our model confirms that age and sex are determinants of
cellular mutation rate, shaping the final mutation composition. We show mathe-
matically for the first time how, similarly to noncancer tissues, melanoma gen-
omes reflect a decline in cell division during ageing. We find that clock-like
mutations strongly correlate with the acquisition of ultraviolet-induced muta-
tions, but critically, men present a higher number and rate of cell-division-linked
mutations.
Conclusions These data indicate that the contribution of environmental damage to
melanoma likely extends beyond genetic damage to affect cell division. Sex and
age determine the final mutational composition of melanoma.
What is already known about this topic?
• Cancer incidence and mortality are influenced by sex and age.
• Melanoma is more frequent in men, and the incidence and mortality rise with
increasing age.
• The main mutations driving melanoma are linked predominantly to ultraviolet
(UV) radiation damage and to errors accumulated in the DNA after each cell divi-
sion, which are unrepaired.
• These clock-like mutations linked to cell division accumulate steadily over time in
both healthy tissue and cancers.
What does this study add?
• Clock and UV mutations are tightly correlated and arise in melanoma as a function
of age and sex.
• The molecular subtypes have a distinct pattern and rate of UV and clock mutations,
and clock mutations depend on the amount of UV damage.
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• The rate of clock mutations decreases as individuals age, reflecting a decrease in tis-
sue proliferation during ageing.
• Men have more clock mutations, which reflect a distinct proliferation rate.
What is the translational message?
• This study indicates that age and sex shape the rate of mutations observed in mela-
noma.
• The burden of mutation affects response to novel immunotherapies, so this work
supports the rationale to stratify patients by their mutational landscape, age and sex
to discriminate possible responders most easily.
• These data can better inform public health prevention campaigns.
Sex and age disparity in cancer incidence and outcomes are
well described, and studies have revealed age1,2 and sex differ-
ences3 in genomics.4,5 Somatic mutations arise in cells due to
damage following cell-intrinsic processes, as well as due to
external environmental damage on the DNA. Recent work
describes computational methods to discern the multiple, dis-
tinct signatures of DNA damage imprinted on DNA depending
on the insult,6 but to date there are no available models to
study the relationship between the distinct damaging processes.
Cutaneous melanoma exemplifies a cancer type primarily
presenting cell-intrinsic (cell division) and environmental (ul-
traviolet radiation, UVR) damaging processes,7 as well as pre-
senting an age and sex bias. Male patients and the aged
population have a higher incidence and rate of death, so we
studied whether the genomic imprints of the major contribu-
tors to total autosomal tumour mutation burden (TMB) in
melanoma are possible sources for the disparity.
Melanoma presents a broad range of clinical subtypes, cate-
gorized by age of onset, history and pattern of UVR expo-
sure.8,9 At one end of the spectrum, we identify elderly
patients with melanomas arising at anatomical sites that have
been chronically exposed to UVR, who have a high TMB. In
contrast, melanoma in younger patients arises decades after
sunburn, over skin that is intermittently exposed to UVR, with
a lower TMB.9–11
The mutually exclusive oncogenic drivers V600BRAF and
NRAS underpin the majority of cutaneous melanomas.12 Loss-
of-function mutations in the tumour suppressor neurofi-
bromin (NF)1 drive an additional subset of cases, and a fur-
ther subgroup is defined by the absence of V600BRAF, NRAS
and NF1 mutations (triple wildtype, W3).13 These genetically
distinct categories overlap to some extent in their clinical char-
acteristics, with V600BRAF being more prevalent in younger
patients.12
Here we examine the relationship between mutational pro-
cesses and their contribution to the melanoma somatic muta-
tion load, and their variation over time and across sexes. We
provide a mathematical framework to model how the specific
damage patterns in DNA arise over time and across the sexes.
Analysing the strong bias in the mutational landscape could
point to key biological differences in how tumours develop
and evolve during ageing and across sexes.
Materials and methods
Mutation data
The primary data are the somatic mutation calls from The
Cancer Genome Atlas (TCGA) Mutation Annotation Format of
the whole-exome sequences of the Skin Cutaneous Melanoma
(SKCM) cohort.10 The sequencing data were obtained from
the TCGA in accordance with ethical guidelines.
We classified samples by their mutations in BRAF with V600
mutations, NRAS, NF1 or none of these genes. Samples with
V600BRAF or NRAS and an additional NF1 mutation were classi-
fied as either V600BRAF or NRAS. We inferred the mutational
processes by categorizing the single-nucleotide substitutions in
the trinucleotide context and used mathematical models to
infer their contribution to the mutational landscape across bio-
logical sex and age.
We estimated the exposure to Signatures 1 and 7 using the
R package deconstructSigs14 and validated the approach by
rederiving the mutation signatures using a hierarchical Dirich-
let process (R package hdp; R Foundation for Statistical Com-
puting, Vienna, Austria).
Mathematical models
The number of mutations present at any given age can be
described using a Poisson process15 with time-varying mean
k tð Þ.15 We use an exponential model k tð Þ ¼ N0eat for the
mean. To estimate the effect of the different subtypes on the
ratio of mutations by age we modelled the accumulation of
mutations using a homogeneous Poisson process with age as
an offset:
log E½NðtÞjX1; . . .; Xk ¼ atþ
X
i
biXi;
where the Xi values are the covariates (sex, site and subtype in
our case). As the distribution of the mutation count data was
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020)
2 Sex and age determine melanoma mutations, Lotz et al.
found to be overdispersed (R package aes), we estimated a
negative binomial regression instead of a Poisson regression.
By fitting a Poisson mixture model, we found similar ratios
between the coefficients associated with the different subtypes.
We estimated the change in accumulation rate with age with
the exponential model for mutation accumulation:
NðtÞ ¼ N0eat; the derivative of fðtÞ ¼ eat=t by t is df
dt
¼ e
at
t
ða 1
t
Þ:
Using the exponential accumulation model, N tð Þ ¼ EN0eat,
where E (for extrinsic mutations) denotes the number of Sig-
nature 7 mutations (Poisson regression with the logarithm of
Signature 7 as offset), we estimated the ratio N tð Þ=E of intrin-
sic, clock-like mutations when factoring out the extrinsic, Sig-
nature 7 mutations.
Additional methods are described in Appendix S1 (see Sup-
porting Information), including mutation data, mutation sig-
natures, the mathematical model of mutation accumulation,
change in accumulation rate with age and cell-cycle gene
expression analysis.
Results
Clock-like and ultraviolet radiation-driven mutations
accumulate with age at distinct rates in the molecular
subtypes of melanoma
We catalogued the base substitutions in 396 whole-exome
cutaneous melanoma samples from TCGA (TCGA-SKCM)12
according to 96 categories defined by the base substitution
and the preceding and following bases.7 In total, 172 had a
V600BRAF mutation, 96 NRAS and 44 NF1, and 84 samples were
non-BRAF, non-NRAS and non-NF1 (W3; Table S1; see Sup-
porting Information).
We inferred the mutational signatures that account for the
somatic mutations from the TCGA data. We extracted the
DNA mutational signature linked to UVR (Signature 7, COS-
MIC database), which is present to varying degrees across
melanomas. Next, we identified the intrinsic, age-related sig-
nature observed in normal cells and cancers with high cell
turnover, which corresponds to spontaneous deamination of
methylated cytosine residues into thymine at CpG sites that
remain unrepaired due to rapid DNA replication (Signature 1,
COSMIC database).7,16,17 This clock-like mutational process
allows estimation of the number of divisions a cell has under-
gone since its inception. Previous studies have modelled the
potential disruption to the linear acquisition of somatic muta-
tions during ageing that occurs when the neoplastic phase
alters the rate of mutation acquisition, and found across multi-
ple cancer types that clock-driven mutations are linked to
intrinsic cellular division despite neoplastic and oncogenic dri-
ver ontogenesis.16,18
We confirmed a positive correlation between the median
number of Signature 1 mutations per year and age for all
samples (Spearman q = 041, P < 0001; Figure 1a), indicat-
ing that these mutations accumulate with age. NRAS, NF1 and
W3 melanomas presented an increase in the mean Signature 1
mutations with age, but this relationship was less significant
in NF1 and W3 melanomas, likely due to the lower sample
size (NRAS Spearman q = 035, P < 001; Figure 1b). Strik-
ingly, there was no significant rank correlation between Signa-
ture 1 and age in BRAF samples (Spearman q = 003, P =
041). To examine the difference in the rates of Signature 1
mutation accumulation between BRAF, NRAS, NF1 and W3
melanomas, we determined the ratio between the number of
Signature 1 mutations and age, and found significant differ-
ences in the ratios of BRAF and W3 to NF1 melanomas (pair-
wise Wilcoxon rank sum test with Bonferroni correction, P <
00027; Figure 1c), but these were less pronounced for BRAF
and NRAS samples.
Next we examined the relationship between Signature 1
mutations and melanoma cell proliferation by investigating
the gene expression of cell-cycle genes.19 We found a weak
but significant correlation between Signature 1 and both cell-
cycle checkpoint G1/S (P = 003, R = 0107) and G2/M (P =
0016, R = 0121) expression genes. Furthermore, when
dividing the melanomas by high vs. low Signature 1 muta-
tions based on the median, we observed a significantly higher
expression of both G1/S and G2/M genes in the high Signa-
ture 1 group, which was more significant for the G2/M-
expressed genes. Finally, in a multiple regression with the
other factors in the dataset (age, sex and molecular subtype),
Signature 1 was the only factor associated with G1/S and G2/
M gene expression.
We next examined the contribution of Signature 7 muta-
tions and found a progressive increase as patients aged, in
accordance with progressive accumulation of UVR damage
during the course of life (Spearman q = 037, P < 0006; Fig-
ure 1d). However, the rate of mutations varied depending on
the molecular subtype, with no significant correlation found
in BRAF melanomas between Signature 7 and increasing age
(Spearman q = 015, P = 087; Figure 1e), and NRAS sam-
ples showing a steady increase of Signature 7 with age (Spear-
man q = 037, P < 0006). Similarly to Signature 1, there was
a significant difference in the ratio of Signature 7 mutations to
age across the subtypes (P < 003, Mann–Whitney U-test with
Bonferroni correction; Figure 1f).
We investigated the association between Signature 7 (global
UV damage) and the novel probabilistic UV damage signatures
that were more recently defined.13 We calculated the likely
UV-associated mutational signatures with the version 3 signa-
tures, using deconstructSigs for consistency. The correlation
between the sum of the four new signatures (SBS7a, SBS7b,
SBS7c, SBS7d) and the version 2 Signature 7 is > 095 (P <
0001). The vast majority of mutations contributing to these
signatures are SBS7a (median proportion of total Signature 7
per sample = 0474) and SBS7b (median proportion per sam-
ple = 0495). As both signature mutagens encompass the
canonical CC?TT and the atypical frequency of C?T substi-
tutions at a dipyrimidine site that is attributable to UV
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mutagenesis, we retained the original, comprehensive Signa-
ture 7 to strengthen our power to detect associations.
Ageing affects the dynamics of the mutational landscape
Common models of cancer have assumed that mutations accu-
mulate at a linear rate over time.20 Genetic changes accumu-
late from early life,16,18 and a decline in replicative function
with age is visible in many tissues.21 We used our cohorts to
test the relationship between ageing and clock-like mutation
rate in melanoma, and found that the ratio of mutations per
year decreases with age (Spearman q = 034, P < 0005;
Figure 2b). Specifically, the decline in mutations per year is
pronounced in BRAF (Spearman q = 044, P < 0001) but
not statistically significant in NRAS or W3 melanomas. We did
not include NF1 samples in the analysis, as this subtype is
almost exclusive to the elderly.
To analyse the differences in ageing dynamics, we con-
sidered the mean number of mutations at each age, mod-
elled by a Poisson distribution with age-dependent rate, and
found that the ratio of mutations by age decreases in older
age groups (Figure 2a). We used an overdispersed Poisson
(negative binomial) regression to estimate the parameters of
the exponential model for each subtype BRAF, NRAS and
W3, and found that overall, the amount of Signature 1
mutations increases by a multiplicative factor of ea = 1012
per year (Figure 2c). In contrast, the increase factor is only
1005 for BRAF, 1016 for NRAS and 1024 for W3 mela-
nomas (Figure 2d; and Tables S2 and S3; see Supporting
Information). Thus, while the ratio of Signature 1 damage
acquisition to age in BRAF and NRAS melanomas decreases
during ageing, likely reflecting a deceleration of the cell
proliferation rate during maturity, the ratio per year of
clock mutations in W3 melanomas slightly increases during
the human lifespan, reflecting a distinct behaviour (Fig-
ure 2e).
The rate of clock-like mutations is linked to ultraviolet
radiation damage
Previous experiments showed that acute UVR drives melano-
cyte proliferation,22 but the long-lasting effects of UVR on cell
division have not been explored. We investigated the propor-
tion of Signature 1 and Signature 7 across the melanoma sub-
types and found that UVR underpins approximately 75% of all
mutations in BRAF, NRAS and NF1 samples, while only half
of the mutations in W3 samples are accounted for by UVR
(Figure 3a). Furthermore, we found a greater proportion of
the ageing signature that is uncoupled from cellular division
(Signature 5, characterized by T:A?C:G transitions) contribut-
ing to the overall mutational burden of W3 melanomas. The
underlying biological process driving Signature 5 mutations is
unknown, but it is linked to ageing independently of cellular
division.18
We then used Signature 1 and 7 to investigate the relation-
ship between UVR damage and the cell cycle, and show that
cell division rate, predicted from Signature 1, tightly correlates
with the total UVR-induced mutations in melanoma (Spear-
man q = 082, P < 0001; Figure 3b). The correlation
between Signatures 1 and 7 remains significant across all of
the subtypes (BRAF: Spearman q = 070, P < 0001; NRAS: q
= 072, P < 0001; NF1: q = 08, P < 0001; W3: q = 064, P
< 0001; Figure 3c). There is a marked difference in the
increase of Signature 1 that is dependent on Signature 7 in
both BRAF and NRAS melanomas (BRAF: robust regression
with slope 0033, P < 0001; NRAS: robust regression with
slope 0046, P < 0001). These data suggest that UVR
increases the total mutation burden by damaging DNA
directly, but it may also modify the TMB by affecting the
dynamics of cell division. Importantly, these data show that
cell proliferation is coupled to UVR, not age, in BRAF melano-
mas.
Ageing-associated mutations accumulate at different
rates in men and women
Melanomas from men present an overall higher number of
missense mutations than in women, adjusted for age and
relevant clinical covariates.3 We investigated the relationship
between Signature 1 and sex. Critically, we observed that
men present a higher number of Signature 1 mutations per
age (P < 001, Mann–Whitney U-test with Bonferroni cor-
rection; median male-to-female ratio 124; Figure 4a). The
difference is visible in the BRAF and NRAS subtypes (Fig-
ure 4b), although it is less statistically significant (P = 01
for BRAF, P = 06 for NRAS; Mann–Whitney U-test with
Bonferroni correction). For men, we found a significant
rank correlation with age (Spearman q = 045, P < 0001),
but we did not find this for female samples (Spearman q =
012, P = 035; Figure 4a). Using multivariate negative
binomial regression we found that sex affects the rate of
mutation accumulation (P < 0001) and estimated the factor
Figure 1 The molecular subtypes of melanoma present distinct ratios of clock-like and ultraviolet radiation (UVR) mutations per unit of time. (a)
Correlation analysis between age and somatic mutations due to clock-like Signature 1 mutations in cutaneous melanomas. The dots represent the
median number of mutations for each age. (b) Correlation analysis between age and clock-like Signature 1 mutations in the molecular subtypes of
cutaneous melanomas. Dots represent the median number of mutations for each age. (c) Ratio of the number of Signature 1 mutations per year
across the molecular subtypes of cutaneous melanoma. (d) Correlation analysis between age and somatic mutations due to UVR Signature 7
mutations in cutaneous melanomas. The dots represent the median number of mutations for each age. (e) Correlation analysis between age and
UVR Signature 7 mutations in the molecular subtypes of cutaneous melanomas. Dots represent the median number of mutations for each age. (f)
Ratio of the number of Signature 7 mutations per year across the molecular subtypes of cutaneous melanoma. W3, triple wildtype.
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Figure 2 Ageing affects the intrinsic mutation rate of the molecular subtypes. (a) Distribution curves displaying Signature 1 mutation frequency
across age ranges. (b) Correlation analysis between clock-like Signature 1 mutations per year and age in cutaneous melanomas. The dots represent
the median number of mutations for each age. (c) Exponential model for the accumulation of Signature 1 mutations in all melanomas. This curve
models the Poisson mean distribution of mutations at each age, with age-dependent rate. (d) Exponential model for the accumulation of Signature
1 mutations in the molecular subtypes of cutaneous melanoma. This curve models the Poisson mean distribution of mutations at each age, with
age-dependent rate. (e) Change in Signature 1 mutations per year with age across the BRAF, NRAS and triple-wildtype (W3) subtypes.
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by which mutations increase per year in male and female
samples (Figure 4c, d; and Table S3; see Supporting Infor-
mation). We observed that only male samples presented a
factor of mutation increase per year greater than one. The
results remain robust when restricting the analysis to the
molecular subtypes (except for NF1 due to the sample
size), showing an increase in Signature 1 mutations with
age in male samples (Table S3).
We next investigated whether the difference in the rate of
mutation accumulation persists when accounting for the effect
of UVR-driven Signature 7 mutations. Assuming that the num-
ber of Signature 1 mutations is proportional to the number of
Signature 7 (Figure 3b, c), we investigated the ratios of Signa-
ture 1 to Signature 7 across melanomas, adjusted for the effect
of Signature 7 on cell division, and found that there is little to
no increase in Signature 1 mutations per year in either sex.
Moreover, the multiplicative rate of increase of the ratio of
Signature 1 to Signature 7 mutations per year turns out to be
slightly smaller (by 001) in men (Table S4; see Supporting
Information) in all samples, across BRAF and NF1 subtypes,
and is not detected in NRAS and W3. These data imply that
the rate at which clock-like mutations accumulate per year
depends on UVR, and this dependence is stronger in men than
in women. Thus, men and women exposed to equal doses of
UV adjust their cell cycles differently, with men increasing the
rate of cell division.
In summary, our results indicate that the mutation rate due
to cell division is determined by UVR exposure, and men are
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Figure 3 The Signature 7 ultraviolet radiation (UVR) imprint predominates in melanoma and is tightly correlated to cell division Signature 1
mutations. (a) Mutation signature proportions in BRAF, NF1, NRAS and triple-wildtype (W3) cutaneous melanomas. (b, c) Correlation analysis
between somatic mutations due to extrinsic, UVR-driven Signature 7 mutations in cutaneous melanomas and intrinsic, clock-like Signature 1
mutations: (b) all melanomas, (c) by melanoma subtype.
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more susceptible to UVR-induced cell proliferation. In con-
trast, women accumulate fewer Signature 1 mutations, at a
slower rate, despite UVR exposure (Figure 5).
Discussion
Sex and age differences have been observed in cancers.3,23 We
provide a mathematical framework to analyse the relationship
between different damaging processes shaping the mutational
landscape of cancer, and how mutations can reveal the effect
of age and sex on carcinogenesis. We use the predominant
mutational processes of the exomes of cutaneous melanomas,
which are imprinted primarily by the clock-like changes due
to cell division and UVR-driven mutations. Both processes
increase during ageing and are tightly correlated, which poses
the intriguing possibility that UVR not only drives melanoma
by damaging DNA directly, but also may influence the intrin-
sic processes of cell division and damage repair.
We observed that the correlation of mutations to age is
absent in BRAF melanomas, in sharp contrast to NRAS and
NF1 melanomas, where there is a gradual increase in UVR
and cell division mutations with patient age. Although our
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Figure 4 Melanomas in men accumulate more Signature 1 mutations. (a) Difference in Signature 1 mutations per age between male and female
samples. (b) Difference in Signature 1 mutations per age between male and female samples by subtype (BRAF and NRAS). (c) Exponential model
for accumulation of Signature 1 mutations by sex. This curve models the Poisson mean distribution of mutations at each age, with the age-
dependent rate. (d) Change of Signature 1 mutations per age over time, according to sex.
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2020)
8 Sex and age determine melanoma mutations, Lotz et al.
correlation studies do not imply causation, the punctuated rate
of mutation accumulation we observe in BRAF melanomas
could be driven by episodic sunburn. Our model supports
clinical studies showing that BRAF melanomas are more preva-
lent over intermittently sun-exposed skin with little sun dam-
age in the dermis of younger patients.24–26 Additionally, our
data corroborate mouse studies demonstrating a link between
few episodic UV exposures and BRAF melanoma.22,27 How-
ever, in addition to the UV-induced DNA mutation burden,
UV also contributes to tumorigenesis by triggering inflamma-
tion,28 and this contribution of UV is not captured by our
model.
Recent studies examining the correlation between lifetime
risk of cancer and cell division have shown that tissues with
higher cell turnover present an increased cancer incidence,29,30
suggesting that more proliferative tissues require less environ-
mental damage to drive tumorigenesis. Our results challenge
this assumption and propose that extrinsic processes such as
UVR can modulate the contribution of cell division to muta-
tion burden.
We show that the decline in cell division during ageing in
healthy tissues and stem cells21,31 is discernible in the geno-
mic imprint of melanoma cells. Moreover, the rate of prolifer-
ative decline is not uniform across all subtypes. Our
framework could test whether the decline in cell division with
age varies according to the tissue of origin, and whether
decline in cell division mirrors a decrease in cancer incidence
observed in the superaged population.
Finally, we reveal an increase in cell-division-linked muta-
tions in men, which could be due to an increase in the inher-
ent proliferation rate of male melanocytes, or to a decrease in
the mutational repair of UVR mutations. A recent pan-cancer
analysis has shown sex biases in mutational load, tumour evo-
lution and mutational processes, and also at the gene
level.4,5,32 Our study suggests that sex differences in mela-
noma cannot be explained by lifestyle or age alone, and likely
reflect sex-specific biology. Intriguingly, Signature 1 is
increased in women in an age-adjusted, pan-cancer analysis,32
while our results reveal a contrary sex bias in Signature 1 in
melanoma.
One limitation of applying mutational signatures to infer
disease evolution is that different mutational stresses occur
at different timepoints of disease progression. In mela-
noma, UV damage is acquired when melanoma is located
in the skin. In contrast, Signature 1 summarizes cell divi-
sions throughout the lifespan of the cell, from premalig-
nancy to advanced stages. However, recent work found
most melanoma mutations to be primarily early, truncal
and monoclonal.33
Our study provides new tools to examine the rate of muta-
tion accumulation in cancer, and to study how sex and age
contribute to tumour development. Tumour burden, age and
sex are known to influence the response to immunothera-
pies,34,35 and future studies should address how these data
can be leveraged to predict response to therapy and design
strategies to improve survival. Although it is limited to a sin-
gle melanoma cohort, this work supports the rationale for
using the mutational processes, together with age and sex, to
stratify patients for novel immunotherapy trials, as well as to
inform public health prevention and diagnostic campaigns.
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